|
MODELS COULD HELP SPEED DISCOVERY OF NEW DRUGS
17 February 2006 - ESI Group
| In an important step toward accelerating drug discovery, researchers have created computer models of more than 900 cell receptors from a class of proteins known to be important drug targets. The models, which are now freely available to noncommercial users, promise to help scientists narrow their research inquiries, potentially speeding up the discovery of new drug compounds. The research appears in the February 17, 2006 issue of the Public Library of Science Computational Biology. |
In an important step toward accelerating drug discovery, researchers have created computer models of more than 900 cell receptors from a class of proteins known to be important drug targets. The models, which are now freely available to noncommercial users, promise to help scientists narrow their research inquiries, potentially speeding up the discovery of new drug compounds. The research appears in the February 17, 2006 issue of the Public Library of Science Computational Biology. This GPCR's specific function is still unknown. The database could help scientists determine the function of receptors like this one, potentially uncovering new drug targets. "This is the first time anyone has modeled them all with an algorithm that improves the accuracy of the structure," said Jeffrey Skolnick Georgia Research Alliance Eminent Scholar in Computational Systems Biology at the Georgia Institute of Technology. "I think it's going to have significant impact, because it's a major class of drug design." One of the hottest areas in drug research, rational drug design uses three-dimensional computer simulations to study how different drugs and their cellular targets interact with each other. This technique can help research teams discover which compounds are most likely to achieve the desired results, potentially accelerating the speed of drug research and allowing for the discovery of reactions that may not have been found through traditional means. G protein-coupled receptors are targeted by an estimated one-third of all drugs and convey chemical signals from the outside of cells to the inside. But because they tend to fall apart once they're removed from the outer membrane of the cell, scientists have only been able to solve the three-dimensional structure for a few of them. And those aren't even good drug targets. Until now, researchers wanting to model any of the others have had to base their models on the structures of the existing, non-pharmacological receptors. Since those receptors, according to Skolnick, are evolutionarily distant from the proteins thought to be good drug targets, the models aren't very accurate. Using an algorithm they developed known as TASSER, a team of researchers led by Skolnick, then at the University of Buffalo, created three-dimensional structures of all the GPCRs below 500AMino acids in the human genome. "The solved GPCRs are of the same approximate shape as the ones known to be good drug targets, only they differ in details. But it's the details, the packing of the helixes, their angles, their size, that differentiate the drug binding sites of GPCRs from one another," said Skolnick, "TASSER appears to have the capacity to give us a reasonable picture of the structure of these proteins." Of the 907 models TASSER has helped create, Skolnick estimates that about 820 are accurate enough to be useful to researchers. "There's still room for significant improvement. They're like cartoons – they kind of look like reality sometimes, but they can be used to help design experiments," said Skolnick. The mission of the Center for the Study of Systems Biology at Georgia Tech, of which Skolnick is the director, is to essentially simulate life on a computer by building accurate three-dimensional models of the components of life, such as individual proteins and collections of proteins. "The idea is to simulate these proteins, introduce a drug structure and see how they interact," said Skolnick.
http://www.esi-group.com
About: ESI Group
ESI Group is the world leading software editor for the numerical simulation of prototype and manufacturing process engineering in applied mechanics. The key to ESI Group's success is the use of realistic material physics, providing "as good as real" virtual solutions, in order to replace the lengthy trial and error processes on real prototypes.ESI Group has developed an entire suite of coherent industry-oriented applications to realistically simulate a product's behavior during testing, to fine tune the manufacturing processes in synergy with the desired product performance, and to evaluate the environment's impact on product usage. ESI Group's product portfolio, which has been industrially validated and combined in multi-trade value chains, represents a unique collaborative, virtual engineering solution, known as the Virtual Try-Out Space (VTOS), enabling a continuous improvement on the virtual prototype. By drastically reducing costs and development lead times, VTOS solutions offer major competitive advantages by progressively eliminating the need for physical prototypes. A sustained growth Total consolidated revenue for fiscal year 2003, ending January 31st 2004, increased by 15% in real terms and 22% at constant exchange rates, compared to the previous year reaching 49 million euro. The software activity remained stable with 73% from licenses and 27% from services. The major acquisitions made in 2002 and 2003 accounted for 15% of revenue growth and took part in the strengthening of the Group's position on the American market. As in previous years, ESI Group maintained a strong international presence with 50% of turnover generated outside Europe and 79% of revenue outside. Listed on the Nouveau Marché of Euronext Paris, ESI Group employs almost 500 high-level specialists worldwide. ESI Group and its global network of agents provide sales and technical support to customers in more than 30 countries. A key investment area: Research and Development ESI Group is making substantial R&D efforts and forms partnerships with leading academic and research laboratories in order to offer state-of-the-art solutions. ESI Group also provides high value-added services, worldwide through its subsidiaries located in Europe, Asia and Americas. Consulting projects with strategic industrial partners as well as European R&D contracts exemplify ESI Group's strong engineering knowledge and scientific expertise. |
More News:
For February 2006
From ESI Group
For Design Software
|